Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer

Table 2

Normal expression of 12-LOX and PAI-1 and normalized expression to TBG and PLT in BPH and prostate cancer patients.

	BPH; Mean ± SD; (median)	Prostate cancer; Mean ± SD; (median)	𝑃
12-LOX (ng/mL)	219.6±209.3; (137)	144.6±304.8; (56)	0.0001
PAI-1 (U/mL)	447.0±345.8; (367)	610.8±483.9; (441)	0.1
TBG (kU)	5.81±6.02; (2.8)	6.21±4.03; (6.7)	0.054
PLT (10^3/mm^3)	207±55; (208)	219±69; (211)	0.6
12-LOX/TBG	83.2±111.2; (52.3)	34.1±77.9; (9.3)	0.000005
PAI-1/TBG	217.5±321.6; (120)	151.7±180.9; (90)	0.2
TBG/PLT	0.02±0.02; (0.01)	0.03±0.02; (0.02)	0.13
12-LOX/PLT	1.07±0.97; (0.8)	0.66±1.40; (0.25)	0.00003
PAI-1/PLT	2.28±1.68; (1.7)	2.98±2.57; (2.2)	0.2